Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited has announced the expansion of its SAPPHIRE Study to include Ascension, one of the largest non-profit health systems in the U.S. This inclusion marks the fourth major U.S. healthcare system to join the study, which aims to assess Artrya’s Salix® AI platform and Plaque Dispersion Score for early and effective detection of coronary artery disease. The study is set to commence in early 2026 and will focus on improving patient outcomes, particularly for women who often show no prior symptoms of coronary artery disease. Ascension’s participation is expected to enhance the study’s reach and impact, leveraging its extensive research capabilities and commitment to cardiovascular innovation.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions for the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. Artrya is actively engaged in regulatory and commercial activities across key international markets.
Average Trading Volume: 965,503
Technical Sentiment Signal: Buy
Current Market Cap: A$580.2M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.